'Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM' - Author's reply

被引：0
|
作者：
Broman, Niklas [1 ,2 ]
Feuth, Thijs [1 ,2 ]
Oksi, Jarmo [1 ,2 ]
机构：
[1] Turku Univ Hosp, Dept Infect Dis, Turku, Finland
[2] Turku Univ Hosp, Dept Pulm Dis, Turku, Finland
来源：
CLINICAL MICROBIOLOGY AND INFECTION | 2022年 / 28卷 / 11期
关键词：
D O I：
10.1016/j.cmi.2022.06.028
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：1520 / 1521
页数：2
相关论文
共 50 条
  • [41] OUTCOMES IN INFLAMMATORY ARTHROPATHY PATIENTS HOSPITALIZED FOR COVID-19
    Collins, T.
    Patel, V.
    Babajanians, A.
    Kubomoto, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 228 - 229
  • [42] Tocilizumab Induces Rapid, Sustained Improvement of Inflammatory Markers in COVID-19, With Clinical Improvement in Most Patients
    Morin, Scott J.
    Jani, Chinmay
    Rupal, Arashdeep
    Singh, Harpreet
    Bourque, Daniel
    Colgrove, Robert C.
    AMERICAN JOURNAL OF THERAPEUTICS, 2021, 28 (05) : E592 - E596
  • [43] The Impact of Early Phase COVID-19 Vaccination on Hospitalized COVID-19 Patients
    Gullu, Yusuf Taha
    Kulucan, Ebru
    Tuna, Nazmiye Tibel
    Koksal, Nurhan
    Koca, Nizameddin
    TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE, 2022, 257 (02): : 147 - 151
  • [44] Elevated liver enzymes in hospitalized patients with COVID-19 in Singapore
    Ngiam, Jinghao Nicholas
    Chew, Nicholas
    Tham, Sai Meng
    Lim, Zhen Yu
    Li, Tony Yi-Wei
    Cen, Shuyun
    Tambyah, Paul Anantharajah
    Santosa, Amelia
    Muthiah, Mark
    Sia, Ching-Hui
    Cross, Gail Brenda
    MEDICINE, 2021, 100 (30) : E26719
  • [45] Tocilizumab in Hospitalized Patients with COVID-19: A Meta Analysis of Randomized Controlled Trials
    Vijairam Selvaraj
    Mohammad Saud Khan
    Chirag Bavishi
    Kwame Dapaah-Afriyie
    Arkadiy Finn
    Amos Lal
    Eleftherios Mylonakis
    Lung, 2021, 199 : 239 - 248
  • [46] NON-CLASSICAL HLA, LEVELS OF INFLAMMATORY MARKERS AND DEMOGRAPHCS IN HOSPITALIZED COVID-19 PATIENTS
    Kanangat, V.
    Piggott, S.
    Christian, E.
    Parmakova, N. T.
    Skaljic, I.
    DeCresce, R.
    HUMAN IMMUNOLOGY, 2022, 83 : 152 - 154
  • [47] Use of Tocilizumab in hospitalized patients during the first wave of the COVID-19 pandemic
    Javier Carrera-Hueso, Francisco
    Alvarez-Arroyo, Laura
    Robustillo-Villarino, Montse
    Perez-Olaso, Oscar
    El-Qutob, David
    Martinez-Martinez, Fernando
    ARS PHARMACEUTICA, 2022, 63 (02) : 166 - 172
  • [48] Tocilizumab in Hospitalized Patients with COVID-19: A Meta Analysis of Randomized Controlled Trials
    Selvaraj, Vijairam
    Khan, Mohammad Saud
    Bavishi, Chirag
    Dapaah-Afriyie, Kwame
    Finn, Arkadiy
    Lal, Amos
    Mylonakis, Eleftherios
    LUNG, 2021, 199 (03) : 239 - 248
  • [49] THERAPEUTIC OUTCOMES FOLLOWING TOCILIZUMAB ADMINISTRATION IN PATIENTS WITH SEVERE COVID-19
    Kline, Jonathan
    Patel, Payal
    Palma, Stephanie
    Pasqualicchio, Michael
    Clarke, Heidi
    CRITICAL CARE MEDICINE, 2021, 49 (01) : 84 - 84
  • [50] Tocilizumab in hospitalized patients with severe COVID-19: an open label, prospective study
    Karampitsakos, Theodoros
    Malakounidou, Elli
    Papaioannou, Ourania
    Dimakopoulou, Vassilina
    Zarkadi, Eirini
    Katsaras, Matthaios
    Tsiri, Panagiota
    Tsirikos, Georgios
    Oikonomou, Ioanna
    Davoulos, Christos
    Georgiopoulou, Vasiliki
    Sampsonas, Fotios
    Marangos, Markos
    Akinosoglou, Karolina
    Tzouvelekis, Argyris
    EUROPEAN RESPIRATORY JOURNAL, 2021, 58
12345